Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Holders of 5% or more of ENTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Entera Bio Ltd., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Opko Health, Inc. | 13G | 8.10%3.69M shares | New | Apr 2, 20251 filing | Apr 2, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Entera Bio Ltd., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20254:06 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 2.60%1.18M shares | −4.20 ppfrom 6.80%Below 5% | Sep 30, 2025 | SEC |
| Apr 2, 20256:51 PM ET | Opko Health, Inc. | 13G | 8.10%3.69M shares | New | Mar 16, 2025 | SEC |
| Jan 6, 20254:10 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 6.80%2.70M shares | New | Jan 3, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Entera Bio Ltd. shares.
No Form 144 notices for Entera Bio Ltd. are on file.